Women and hypertension;Frauen und hypertonie

Herz

Volumn 30, Issue 5, 2005, Pages 401-404

  Mitchell, Anna ^c   Philipp, Thomas ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c NONE

Author keywords

Calcium antagonists; Cardiovascular risk; Diuretics; Gender; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COUGHING; ELECTROLYTE DISTURBANCE; FEMALE; HUMAN; HYPERTENSION; MORBIDITY; PATIENT COMPLIANCE; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DIET THERAPY; FEMALE; GERMANY; HUMANS; HYPERTENSION; INCIDENCE; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL RATE;

EID: 24144437380     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2711-8     Document Type: Article

References (30)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
2. August P, Oparil S. Hypertension in women [Commentary]. J Clin Endocrinol Metab 1999;84:1862-6.
3. Boersma E, Keil U, De Bacquer D, et al., EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003;21:1831-40.
4. Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey 1988-1991, Hypertension 1995;25:305-13.
5. Calhoun DA, Oparil S. The sexual dimorphism of high blood pressure. Cardiol Rev 1998;6:356-63.
6. Chambless L, Keil U, Dobson A. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of trends and determinants in Cardiovascular Disease. Circulation 1997;96:3849-59.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72.
8. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
9. Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. VA I - Study. JAMA 1967;202:1028-34.
10. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. VA II - Study. JAMA 1970;213:1143-52.
11. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
12. Gasse C, Hense HW, Stieber J, et al. Factors associated with differences in antihypertensive drug treatment: results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95. Soz Präventivmed 2002;47:128-42.
13. Gasse C, Stieber J, Doring A, et al. Population trends in antihypertensive drug use: results from the MONICA Augsburg Project 1984 to 1995. J Clin Epidemiol 1999;52:695-703.
14. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials.The INDANA Investigators. Ann Intern Med 1997;126:761-7.
15. Kanai H, Tokunaga K, Fujioka S, et al. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996;27:125-9.
16. Keil U, Kuulasmaa K. WHO MONICA Project: risk factors. Int J Epidemiol 1989;18:46-55.
17. Lewis CE. Characteristics, treatment of hypertension in women: a review of the literature. Am J Med Sci 1996;311:193-9.
18. Lewis CE, Grandits A, Flack J, et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results from the Treatment of Mild Hypertension Study. Arch Intern Med 1996;156:377-85.
19. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999;47:111-4.
20. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
21. Os I, Bratland B, Dahlof B, et al. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992;339:339-72.
22. Quan A, Kerlikowske K, Gueyffier F, et al., INDANA Investigators. Pharmacotherapy for hypertension in women of different races. Cochrane Database Syst Rev 2000;3:CD002146.
23. Reyes D, Lew SQ, Kimmel PL. Gender differences in hypertension and kidney disease. Med Clin North Am 2005;89:613-30.
24. Wassertheil-Smoller S, Anderson, G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women. Hypertension 2000;36:780-9.
25. Wassertheil-Smoller S, Psaty BM, Greenland P, et al. Association between cardiovascular outcomes and anti-hypertensive drug treatment in older women. JAMA 2004;292:2849-59.
26. WHI StudyGroup. Design of the Women's Health Initiative clinical trial and observation study. Control Clin Trials 1998;19:61-109.
27. Wilansky S, Wollerson JT. Heart disease in women. New York: Churchill Livingstone, 2002:chapter 19.
28. Wing LM, Reid CM, Ryan P, et al., Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
29. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9.
30. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.